Our results suggest sstr as an independent prognostic marker in NETs. Sstr-immunohistochemistry correlates with sstr-imaging; however, sstr-imaging is more accurate for determining the individual prognosis.

Background: Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data (IPD) meta-analysis including all published meningioma patients treated with SSTR-targeted PRRT. Main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers, and identified six eligible cohort studies. We included a total of 111 patients with treatment-refractory meningioma who received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. Six-month PFS was 94%, 48% and 0% for WHO (World Health Organization)-I,-II, &-III, respectively. The risk of disease progression decreased by 13% per 1000 MBq increase in the total applied activity. One-year OS was 88%, 71%, and 52% for WHO-I,-II &-III, respectively. The risk of death decreased by 17% per 1000-MBq increase of the total applied activity. Main side effects comprised transient hematotoxicities such as anemia in 22%, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17% of patients. Conclusion: This IPD meta-analysis represents the most comprehensive analysis of benefits and adverse events of SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising PFS and OS.

Purpose: To determine the thyroid clearance effective half-life with a common handheld electronic dosimeter (ED) in patients undergoing radioiodine treatment for hyperthyroidism.Methods: Dose rates from twelve inpatients were measured daily with an ED and with a clinical uptake counter. The ED was attached to the patient with two different setups, one using a cervical collar and another employing a neck strap. Estimation of was performed by linear regression analysis of the log of both the ED and the uptake counter measurements versus time. The latter provided the reference data.Results: Based on repeated neck strap dose rate measurements, individual s were determined with clinically required accuracy. The mean difference from the reference method equaled to -0.090.35 days. Conclusions:Determination of individual is feasible with a common handheld ED using the simple and easy to instruct neck strap measurement setup. This simple method complements stationary uptake counter measurements and thus may improve the accuracy of radioiodine treatment planning by adding an individual for dose calculation..

No abstract